In 2017, the global pemetrexed market was valued at approximately 2,062 million.
Pemetrexed disodium is a chemotherapy drug used in the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC). The generic version of the drug is named pemetrexed. Currently, it is available in powder form, which is then converted to a solution for intravenous infusion.
According to Cancer Research UK, lung cancer is the third most prevalent in the U.K, which accounted for approximately 13% of all the new cancer cases occurring in a year. Moreover, it was the second most common cancer type in males as 24,500 new cases were registered in 2015. Over the last decade, the prevalence of cancer has been increased by 3%, which, in turn, has influenced the pemetrexed market in the U.K.
According to the National Cancer Institute, 228,150 new cases of lung cancer are estimated to be registered in the U.S. by the end of 2019, which makes up almost 12.9% of the total number of cancer cases. The increasing level of pollution in the developed and developing regions such as North America, Europe, and the Asia Pacific is driving the global pemetrexed market.
However, adverse effects of chemotherapy and the launch of new substitute treatments for lung cancer are likely to hamper the market growth in the near future.
The global pemetrexed market is segmented by application, end-user, and region.
The market is segmented into malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC). The mesothelioma segment is expected to dominate the global market owing to the high prevalence of lung cancer in developed and developing regions.
Based on End-user
The market is segmented into hospitals/clinics, oncology centers, offline pharmacies, online pharmacies, and others. The hospitals/clinics segment is expected to account for the largest share of the market due to the increasing number of hospitals and clinics across the globe. The oncology centers segment is anticipated to account for an optimum share of the global market due to the technologically advanced services provided by the oncology centers. The others segment comprises research laboratories, which are forecasted to account for a significant share of the market owing to the ongoing research in oncology.
By region, the global pemetrexed market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global pemetrexed market in 2018 and is expected to continue the same during the forecast period 2019–2026. The prevalence of lung cancer patients in the U.S. is increasing rapidly as a result of increasing pollution levels, changing lifestyles, and constantly increasing demand for pemetrexed in the U.S. oncology market due to the high efficiency of the drug.
Europe is anticipated to account for an optimum share of the global pemetrexed market owing to a significant presence of Eli Lilly and Company in the region, which has exclusivity patented pemetrexed in the U.K till 2021. Growing demand for the drug in chemotherapy treatments for lung cancer is escalating the regional growth further.
The Asia Pacific is expected to be the fastest-growing region for the pemetrexed market on account of a growing number of cancer patients in the region. For instance, the large production of chemical raw materials in China has increased the prevalence of lung cancer.
LAMEA is anticipated to account for the least market share with a sluggish growth rate due to poor healthcare infrastructure and low income of people in Africa. Limited government support for cancer treatment has been restraining the market growth in the region for the last decade. However, significant improvements in the healthcare facilities in Argentina and Brazil are anticipated to flourish market growth to some extent.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|